Pasar al contenido principal

NANOHERRAMIENTAS TERAPEUTICAS Y DIAGNOSTICAS PARA CANCERES Y ENFERMEDADES NEUROMUSCULARES RARAS BASADAS EN ACIDOS NUCLEICOS Y CRISPR

PID2023-146982OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION IMDEA NANOCIENCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Aptamer-conjugated gold nanoparticles enable oligonucleotide delivery into muscle stem cells to promote regeneration of dystrophic muscles

  • Millozzi, Francesco
  • Milán-Rois, Paula
  • Sett, Arghya
  • Delli Carpini, Giovanni
  • De Bardi, Marco
  • Gisbert-Garzarán, Miguel
  • Sandonà, Martina
  • Rodríguez-Díaz, Ciro
  • Martínez-Mingo, Mario
  • Pardo, Irene
  • Esposito, Federica
  • Viscomi, Maria Teresa
  • Bouché, Marina
  • Parolini, Ornella
  • Saccone, Valentina
  • Toulmé, Jean-Jacques
  • Somoza, Álvaro
  • Palacios, Daniela
Inefficient targeting of muscle stem cells (MuSCs), also called satellite cells, represents a major bottleneck of current therapeutic strategies for muscular dystrophies, as it precludes the possibility of promoting compensatory regeneration. Here we describe a muscle-targeting delivery platform, based on gold nanoparticles, that enables the release of therapeutic oligonucleotides into MuSCs. We demonstrate that AuNPs conjugation to an aptamer against α7/β1 integrin dimers directs either local or systemic delivery of microRNA-206 to MuSCs, thereby promoting muscle regeneration and improving muscle functionality, in a mouse model of Duchenne Muscular Dystrophy. We show here that this platform is biocompatible, non-toxic, and non-immunogenic, and it can be easily adapted for the release of a wide range of therapeutic oligonucleotides into diseased muscles., This work was funded by the Eranet-Euronanomed Joint Call 2016 (H2020), project #ER-2016-2360733 to D.P, A.S., and J-J. T and the French Association Against Myopathies, Ignition project #23592 to D.P and A.S. Also, it was partially supported by the Spanish Ministry of Economy and Competitiveness [PID2020-119352RB-I00, PID2023-146982OB-I00], Comunidad de Madrid [S2022/BMD‑7403 RENIM‑CM], Asociación Española Contra el Cáncer (PRYCO223002PEIN), and IMDEA Nanociencia. F.M. acknowledges a PhD fellowship from Università Sapienza, G.D.C. acknowledges a PhD fellowship from Università Cattolica del Sacro Cuore. M.M. acknowledges support from Ministerio de Ciencia e Innovación (FJC2021-048151-I). I.P. acknowledges a PhD fellowship from the Community of Madrid (Grant No: PIPF‑2022SAL‑GL‑24788). IMDEA Nanociencia receives support from the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (MICINN Grant no: CEX2020‑001039‑S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gemcitabine and miRNA34a mimic codelivery with magnetic nanoparticles enhanced anti-tumor effect against pancreatic cancer

  • Lafuente-Gómez, Nuria
  • Martínez-Mingo, Mario
  • Díaz-Riascos, Zamira Vanessa
  • García-Prats, Belén
  • de la Iglesia, Irene
  • Dhanjani, Mónica
  • García-Soriano, David
  • Campos, Luis A
  • Mancilla-Zamora, Sandra
  • Salas, Gorka
  • Abasolo, Ibane
  • Somoza, Álvaro
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jconrel.2025.113791., Pancreatic ductal adenocarcinoma is a highly aggressive cancer with a low survival rate. Thus, efforts are needed to develop more effective treatments. Herein, we propose utilizing magnetic nanoparticles (MNP) for the concurrent delivery of gemcitabine and miRNA34a mimic to target pancreatic cancer cells. The MNP were functionalized with disulfide bonds to selectively release their cargo inside tumor cells. The incorporation of the miRNA34a mimic increased the sensitivity of cells to gemcitabine, especially in BxPC-3 cells. Additionally, the miRNA34a sequence was modified with locked nucleic acids (LNA) to increase stability. The resulting LNA34a showed a stronger cytotoxic effect when combined with gemcitabine, even in PANC-1 cells, which are resistant to the drug. Notably, the modified MNP exhibited less toxicity than their free counterparts when incubated with HaCaT cells, a model of healthy keratinocytes. Additionally, the combined delivery of miRNA34a mimics and gemcitabine using MNP elicited a synergistic cytotoxic effect against pancreatic cancer cells through magnetic hyperthermia. The intratumoral administration of the modified MNP in subcutaneous xenografts of BxPC-3 cells resulted in a sustained increase in temperature when an alternating magnetic field was applied. Notably, the treatment with the MNP functionalized with GEM and LNA34a led to significant changes in the expression of NOTCH1 and NOTCH2 in the tumor, which are direct targets of miRNA34a, as well as HSP70, which is related to the cellular response to stressors like heat., This work was supported by the Spanish Ministry of Economy and Competitiveness [PID2023-146982OB-I00, PID2020- 119352RB-I00, PID2019-106301RB-I00], Comunidad de Madrid [IND2017/IND-7809; S2017/BMD-3867, IND2020/IND-17517, S2022/BMD-7403 RENIM-CM], Asociación Española Contra el Cáncer [PRYCO223002PEIN], and IMDEA Nanociencia. IMDEA Nanociencia acknowledges support from the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D [MINECO, Grant SEV-2016-0686, CEX2020-001039-S]. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 685795 (NoCanTher) and No 814607 (Safe-n-Medtech). We also acknowledge the European Structural and Investment Fund. Nuria Lafuente-Gómez and Mario Martínez-Mingo thankSpanish Science Ministry [FPU18/02323, FJC2021-048151-I, respectively] for the funding., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tri-Modal Anticancer Strategies with Doxorubicin-Loaded Iron Oxide Nanoparticles Integrating Chemo and Magneto-Photothermal Therapeutic Effects

  • López-Méndez, Rosalía
  • Lafuente-Gómez, Nuria
  • Céspedes, Eva
  • Dhanjani, Mónica
  • París-Ogáyar, Marina
  • Terán, Francisco José
  • Serrano, Aida
  • Camarero, Julio
  • Salas, Gorka
  • Wilhelm, Claire
  • Somoza, Álvaro
  • Espinosa, Ana
In this study, the potential of maghemite (γ-Fe<inf>2</inf>O<inf>3</inf>) nanoparticles (MNPs) functionalized with doxorubicin (DOX) is explored for chemo-magneto-photothermal therapy in cancer treatment. MNPs are functionalized through electrostatic interactions or disulfide bonds, achieving high drug-loading efficiencies. The trimodal approach combines magnetic hyperthermia (MHT), photothermal therapy (PTT) and local chemotherapy, utilizing low and clinically relevant doses. Thermal treatments induced controlled temperature increases, triggering pH-sensitive DOX release in the acidic environments typical of tumors. Efficient uptake of DOX-loaded MNPs is observed, and their structural integrity is confirmed using advanced synchrotron spectroscopic techniques. Cytotoxicity assays show that MHT and PTT together enhanced therapeutic efficacy compared to free DOX, while minimizing toxicity to healthy cells. This study demonstrates that combining thermal therapies with controlled drug release provides a promising strategy for improving cancer treatment outcomes. The findings highlight the potential clinical application of multifunctional nanoparticle systems for targeted, low-toxicity cancer therapies, advancing the path toward more effective and accessible treatments., This work was funded by MCIN/AEI/10.13039/501100011033 (PID2021-127033OB-C21, PID2020-119352RB-I00, PID2020-117080RB-C53, PID2023-146982OB-I00, PID2023-152944OB-I00, PID2024-161273OB-C21), MCIN/AEI/10.13039/501100011033 and the “European Union NextGenerationEU/PRTR" (CNS2023-144689), CSIC (PIE-20226AT024 and Ayudas Incorporación de Científicos Titulares OEP (ref. 2024ICT15)) and Comunidad de Madrid (2018-T1/IND-1005, ASAP-CM S2022/BMD-7434, S2022/BMD-7403 RENIM-CM and TEC-2024/TEC-380 “Mag4TIC”). IMDEA Nanociencia acknowledges support from the Severo Ochoa program for Centers of Excellence in R&D (CEX2020-001039-S) and FPI grant PRE2020-96246 (R.L.-M.). N.L.-G. also thanks the Spanish Science Ministry (FPU18/02323) for the funding. A.S. acknowledges financial support from grant RYC2021–031236-I funded by MCIN/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR”. M.P.O. acknowledges the financial support from MICINN for an FPU (FPU20/03166). This work has been funded with €1.026 million by the Comunidad de Madrid through the LUNABRAIN-CM R&D activities program (TEC-2024/TEC-43), granted by Order 5696/2024. This work was supported by the Severo Ochoa Program for Centers of Excellence in R&D (CEX2024-001445-S), granted to the Instituto de Ciencia de Materiales de Madrid (ICMM-CSIC)., Peer reviewed, Modelo experimental alternativo-NAM, in vitro - Tipos celulares
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting of ibrutinib resistance-driving pathways by miR-28 in ABC-DLBCL

  • Álvarez-Corrales, Emigdio
  • Moreno-Palomares, Rocío
  • Gómez-Escolar, Carmen
  • Martínez, Mario
  • Moral-Pérez, Udane
  • Laguna-Herrero, María
  • Fuertes, Teresa
  • Estrada, Belén S.
  • Mur, Sonia
  • Bonis, Adriana de
  • Leiva, Magdalena
  • Martínez-Martín, Nuria
  • Somoza, Álvaro
  • Ramiro, Almudena R.
  • Yébenes, Virginia G. de
The RNA-seq datasets generated during the current study are available in the ArrayExpress Functional Genomics Data repository (accession number: E-MTAB-16241)., Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma. Although many patients respond well to R-CHOP immunochemotherapy, those with the activated B-cell (ABC) subtype are often refractory or relapse. Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib have improved outcomes, but acquired resistance limits their long-term efficacy. Here, we modeled the development of ibrutinib resistance in ABC-DLBCL and investigated whether the BCR-signaling regulator microRNA-28 (miR-28) can block this process. Using flow cytometry-based competition assays, multicolor clonal barcoding, transcriptomic profiling, and xenograft models, we found that miR-28 expression impairs the emergence of ibrutinib-resistant ABC-DLBCL cells. Mechanistically, miR-28 interferes with the clonal selection process triggered by ibrutinib treatment and rewires transcriptional programs by downregulating mitochondrial and mTOR signaling pathways critical for resistance development. Furthermore, the miR-28-repressed gene signature associated with ibrutinib resistance correlates with improved survival in ibrutinib-treated patients from the PHOENIX trial cohort with the MCD genetic subtype, which is associated with ABC-DLBCL. Finally, the targeted therapeutic delivery of miR-28 via aptamer-guided nanoparticles suppresses ibrutinib-resistant tumor growth in vivo. These findings identify miR-28 as an effective inhibitor of ibrutinib resistance, underscoring its translational potential as an adjunct strategy in ABC-DLBCL therapy., We thank Janssen and the European Genome-phenome Archive for providing access to data from the PHOENIX trial, the members of the B cell biology lab, Balbino Alarcón, José Luis Marina, and María Jesús García de Yébenes for helpful discussions, and Arantzazu Alfranca for providing the LeGO vectors. E.A.C. and R.M.P were supported by PhD fellowships from the Comunidad de Madrid (PIPF-2022/SAL-GL-24469 and PIPF-2023/SAL-GL-29484 respectively), A.R.R. by CNIC funding and V.G.Y. by the Universidad Complutense de Madrid. B.S.E. is supported by a FPI contract from the Spanish Ministry of Science (PRE2022-102696). This work was funded by Spanish Ministerio de Ciencia e Innovación grants PID2019-107551RB-I00/AEI/10.13039/501100011033 and PID2022-137014OB-I00/AEI/10.13039/501100011033/ FEDER, UE to V.G.Y and PID2023-146982OB-I00, CEX2020-001039-S and PID2024-159895OB-100 to A.S, IMDEA Nanociencia and M.L, respectively. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation), and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). N.M.M. lab is supported by the grants CNS2022-135636, PID2021-126298OB-I00, PID2024-162320OB-I00 (founded by MCIU/AEI/10.13039/501100011033/FEDER, UE) and HR22-00447 (founded by La Caixa)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001039-S), With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001041-S), Peer reviewed